EUROBIO SCIENTIFIC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.82 EUR | -0.58% |
|
-1.71% | -16.04% |
| 06-24 | Proteomics International Laboratories Taps French Distributor for Diabetic Kidney Disease Test | MT |
| 05-08 | Eurobio Scientific: agreement with Myriad Genetics | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is in a robust financial situation considering its net cash and margin position.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.93 for the current period. Therefore, the company is undervalued.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -16.04% | 149M | - | ||
| +19.41% | 45.51B | B- | ||
| +38.65% | 38.13B | A | ||
| -8.62% | 38.52B | B | ||
| +26.95% | 30.74B | B | ||
| -13.50% | 26.03B | C | ||
| +10.74% | 25.92B | B- | ||
| +44.87% | 14.13B | B+ | ||
| +34.36% | 12.73B | C+ | ||
| -7.14% | 11.29B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALERS Stock
- Ratings Eurobio Scientific
